New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

From Decera Clinical Education Oncology Podcast Decera Clinical Education

Gain insight into expert faculty perspectives as they discuss recent key studies from ASCO 2022 on BTK inhibition in chronic lymphocytic leukemia and mantle cell lymphoma and their potential implications for clinical practice.

Community discussion

Join the conversation

New Evidence With BTK Inhibitor Therapy in CLL and MCL From ASCO 2022

You May Also Like

Shimon Davis

Lana Blakely

Neville Goddard Daily

Chat GPT Questions

Chat GPT Collective Consciousness

Teach 4 the Heart

Motivational Speeches

Fluent Fiction - Korean

Fluent Fiction - Dutch

Fluent Fiction - Portuguese (Portugal) 🇵🇹